U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    34,281.22
    -149.83 (-0.44%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Autolus Therapeutics plc (NASDAQ: AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and r/r Adult Acute Lymphoblastic Leukemia (ALL) trials.

  • The data were presented at the European Hematology Association Virtual Congress 2021.

  • As of the cut-off date of May 17, obe-cel was well-tolerated and demonstrated a favorable safety profile in adult patients with r/r low-grade B-cell lymphoma, despite a high disease burden.

  • All treated patients achieved complete metabolic remission.

  • Mild cytokine release syndrome (CRS) was reported in 4 patients and moderate CRS in 1 patient.

  • No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.

  • At a median follow-up of 6 months, 8/9 patients were disease-free at last follow-up, with one patient relapsed but was rescued with radiotherapy.

  • One patient died of a COVID-19 infection at month 5.6 while in complete metabolic remission.

  • In 20 patients in Cohort A with r/r ALL, the therapy was well tolerated, with no patients experiencing severe or higher CRS.

  • Three patients, all of whom had high leukemia burden (over 50% blasts), experienced severe ICANS that resolved with steroids.

  • Of the 20 patients evaluable for efficacy, 17 patients achieved a minimum residual disease-negative complete remission at one month.

  • Across all treated patients, event-free survival (EFS) at twelve months and twenty-four months is 50.2%, with median EFS not being reached.

  • The management will host a conference call and webcast today at 8:30 am ET.

  • Price Action: AUTL shares are up 0.7% at $6.90 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.